Real-world treatment and long-term outcomes after autologous stem cell transplantation in first line for myeloma in France and Algeria before the daratumumab era

Key Points

• Long-term outcomes showed a notable durability of response in myeloma patients treated with autologous stem cell transplantation.
• Survival rates demonstrated a 5-year overall survival of approximately 50% in patients undergoing this treatment.
• Observational analysis across two countries highlighted differences in treatment pathways and outcomes before the daratumumab era.
• Findings may guide future treatment decisions and clinical approaches in myeloma care, stressing the importance of ongoing analysis.